To evaluate the therapeutic potential of i-HPK1 in ameliorating post-stroke lung injury, i-HPK1 (2 mg/kg) was administered 30 min after reperfusion following a severe ischemia (90 min of occlusion). This evidence concerns the gene MAP4K1 and stroke disorder.